Information about Service for Anti-Inflammatory Efficacy Testing Service on Human Hair Follicle Cells
VISBIO provides in vitro anti-inflammatory efficacy testing on Human Hair Follicle Dermal Papilla Cells (HFDPCs) — the actual target cells governing the hair growth cycle — using Cytokine (TNF-α or IL-1β) or Lipopolysaccharide (LPS) induction models. Gene expression of key inflammatory markers IL-1β, TNF-α, TGF-β1, and NF-κB is quantified by RT-qPCR, all of which are directly linked to hair loss, hair thinning, and scalp damage. This service is designed for brand owners, OEM manufacturers, and R&D teams who need mechanistic evidence that their active ingredients or formulations genuinely reduce inflammation in hair follicle cells at the molecular level — supporting anti-inflammatory, scalp soothing, and hair loss prevention claims for hair and scalp care products.
Scientific Background
Why Is Anti-Inflammatory Testing on Hair Follicle Cells Important?
Inflammation is one of the fundamental mechanisms underlying multiple forms of hair loss, including Androgenetic Alopecia (AGA), Alopecia Areata, Telogen Effluvium, and Chronic Scalp Inflammation that impairs follicular health over time. Research has shown that pro-inflammatory cytokines, particularly TNF-α and IL-1β, are among the most potent inhibitors of hair follicle growth, with IL-1β demonstrating an IC50 for follicle growth inhibition of as little as approximately 5 pg/mL.
For hair and scalp care products, test data demonstrating that an active ingredient can reduce inflammation in Dermal Papilla cells carries substantial weight in supporting anti-inflammatory and scalp soothing claims — especially in a market where consumers are increasingly focused on Scalp Health. This evidence enables brands to communicate product strengths with scientific backing and differentiate from competitors relying on generic claims without supporting data.
Anti-inflammatory testing on HFDPCs directly addresses this need by measuring efficacy on the actual target cells governing hair health — not on generic cell lines such as RAW264.7 or THP-1 which, while capable of generating anti-inflammatory data, do not specifically reflect effects on hair follicles. Data from HFDPCs is therefore more specific and credible for hair care product development and claims.
How Inflammation Damages Hair Follicles?
The hair follicle is a small organ with a unique immunological property known as Immune Privilege, meaning that under normal conditions the follicle maintains an environment that shields it from immune surveillance. When this Immune Privilege collapses, immune cells attack the follicle, triggering inflammation that disrupts the hair growth cycle.
- Inflammation-driven follicular damage occurs simultaneously across multiple levels. First, pro-inflammatory cytokines — particularly TNF-α and IL-1β — inhibit matrix cell proliferation within the follicle and trigger apoptosis (programmed cell death). Research has demonstrated that TNF-α and IL-1β are the most potent inhibitors of follicular growth among all cytokines tested.
- Inflammation stimulates Dermal Papilla cells to upregulate TGF-β1 secretion. TGF-β1 accelerates the transition of hair follicles into the Catagen (regression) phase, shortening the hair growth cycle, causing follicular miniaturization, and progressively thinning newly grown hair. In Androgenetic Alopecia, androgens further amplify TGF-β1 secretion from balding Dermal Papilla cells compared to non-balding regions, demonstrating that chronic inflammation and androgen signaling cooperate to destroy follicles.
- Chronic inflammation leads to Perifollicular Fibrosis — the formation of fibrous tissue around the follicle — which obstructs the delivery of nutrients and growth factors to the Dermal Papilla. Over time, the Dermal Papilla progressively loses its ability to signal hair growth. Active ingredients capable of reducing inflammation in Dermal Papilla cells therefore have potential to slow or prevent these destructive processes.
The NF-κB Signaling Pathway: Master Regulator of Follicular Inflammation
NF-κB (Nuclear Factor Kappa-light-chain-enhancer of activated B cells) is a transcription factor that serves as the master regulator of inflammatory responses in nearly every cell type, including follicular cells. Under normal conditions, NF-κB is sequestered in the cytoplasm by IκB. When cells receive pro-inflammatory signals such as TNF-α, IL-1β, or LPS, IκB is degraded, allowing NF-κB to translocate into the nucleus and activate the expression of hundreds of inflammation-related genes.
In the follicular context, NF-κB plays a complex dual role. On one hand, NF-κB activity is necessary for maintaining the Anagen (growth) phase of hair. On the other hand, excessive NF-κB activation driven by inflammatory signals suppresses follicular growth and accelerates the transition into Catagen. Research has shown that Dermal Papilla and Dermal Sheath cells in hair follicles display distinct NF-κB response patterns compared to general skin fibroblasts — follicular cells exhibit acute NF-κB activation when stimulated with TNF-α and IL-1β, yet show greater tolerance to LPS as part of their Immune Privilege mechanism.
Understanding this mechanism is critical for test design. VISBIO employs both the Cytokine (TNF-α/IL-1β) model and the LPS model to cover distinct inflammatory induction pathways. Test substances capable of reducing NF-κB activation or suppressing downstream NF-κB target gene expression demonstrate clear potential to protect hair follicles from inflammation-induced damage.
Scope of VISBIO Testing Services
VISBIO provides anti-inflammatory efficacy testing on HFDPCs using two inflammation induction models: Cytokine stimulation (TNF-α or IL-1β) to simulate acute cellular inflammation, and Lipopolysaccharide (LPS) stimulation via TLR4 Signaling for comprehensive NF-κB Pathway activation. This dual-model design allows brand owners to select the model best suited to their product objectives and target claims. Testing is structured across as follows.
Cytotoxicity Assay
Before anti-inflammatory testing begins, VISBIO conducts a preliminary Cytotoxicity assessment via MTT Assay to evaluate the effect of the test substance at various concentrations on the viability of HFDPCs under normal conditions — without any inflammatory stimulus. This step is critical for establishing the Sub-Cytotoxic Concentration Range at which the test substance itself causes no cellular toxicity, ensuring that subsequent RT-qPCR results reflect genuine anti-inflammatory activity rather than cytotoxic artifacts.
Results are expressed as a % Cell Viability curve across tested concentrations. VISBIO selects the appropriate dose for subsequent RT-qPCR testing — typically the concentration at which Cell Viability remains ≥ 80% — ensuring test results are reliable and interpretable.
Inflammatory Gene Expression Measurement via RT-qPCR
The core of VISBIO’s service is molecular-level testing, delivering mechanistic data on how a test substance acts on inflamed cells. Following inflammation induction in HFDPCs and application of the test substance at a safe dose, VISBIO performs Cell Lysate, RNA Extraction, cDNA Synthesis, and RT-qPCR (Real-Time Quantitative PCR) to quantify target gene expression across all treatment groups. Results are reported as Fold Change relative to the control group — clear quantitative data that can be directly cited in technical claims. Target genes are grouped by induction model as follows.
| Induction Model | Target Genes (RT-qPCR) | Biological Significance |
| TNF-α or IL-1β (Cytokine Model) | IL-1β, TNF-α, TGF-β1 | Measures pro-inflammatory cytokines and Catagen inducers directly |
| LPS (TLR4/NF-κB Model) | NF-κB (RELA/p65) | Measures the master regulator of Inflammatory Response |
RT-qPCR data are reported relative to the control group. If the test substance significantly reduces Pro-inflammatory gene expression, this indicates that the substance demonstrates anti-inflammatory activity at the transcriptional level.
Understanding what each gene represents helps brand owners identify the right testing targets for their specific product objectives.
- Elevated IL-1β → Associated with Acute Hair Loss, as IL-1β is the most potent follicular growth inhibitor among all cytokines tested.
- Elevated TNF-α → Associated with Hair Thinning and Scalp Irritation, as TNF-α suppresses matrix cell proliferation and promotes perifollicular inflammation.
- Elevated TGF-β1 → Associated with Permanent Hair Thinning, as TGF-β1 accelerates entry into the Catagen phase, permanently shortening the hair growth cycle.
- Elevated NF-κB Activation → Acts as the molecular inflammation switch, simultaneously controlling hundreds of pro-inflammatory gene expressions. It is the most comprehensive biomarker for evaluating anti-inflammatory activity in hair follicle cells.
Cell Imaging
VISBIO provides cell imaging of HFDPCs using an Inverted Microscope to compare cellular morphology and cell density across treatment groups. Imaging provides a visual, tangible representation effects and can be incorporated into research reports or product claim documentation.
Products Suitable for This Service
The Anti-Inflammatory ROS Assay on Hair Follicle Cells is suitable for a broad range of products across the Health & Beauty industry — particularly those carrying Anti-Inflammatory claims
| Examples | |
| Cosmetics | Hair serums, shampoos and conditioners, scalp tonics, hair oils | |
| Dietary Supplements | Hair nourishing supplements containing anti-inflammatory actives such as Curcumin, Resveratrol, and EGCG | |
| Active Ingredients | Anti-inflammatory peptides, herbal extracts, essential oils with anti-inflammatory properties, and novel active ingredients requiring efficacy data to support product development | |
| Herbal Extracts | Extracts or active ingredients that already have anti-inflammatory data from other testing systems (e.g., RAW264.7 cells or Nitric Oxide Assays) — adding HFDPC-specific data confirms that the observed activity translates directly to hair follicle cells, providing high-value evidence for both product development and hair care marketing |
Benefits of Anti-Inflammatory Efficacy Testing Service on Human Hair Follicle Cells
- Anti-Inflammatory / Scalp Soothing Claim Support RT-qPCR data demonstrating that a test substance reduces IL-1β, TNF-α, or NF-κB expression in Dermal Papilla cells serves as a laboratory-level (in vitro) scientific evidence base to support the efficacy evaluation of active ingredients and hair care products.
- R&D Data Anti-inflammatory data from HFDPCs supports R&D teams in active ingredient screening, comparative testing of multiple candidates on the same target cells, optimal concentration determination, and understanding molecular mechanisms of action — all toward developing maximally effective formulations.
- Product Differentiation In the highly competitive hair care market, scientific test data from HFDPCs differentiates products from those relying on generic claims. RT-qPCR results showing quantified reductions in pro-inflammatory gene expression provide clear, communicable data equally accessible to scientific experts and business executives. This data can be leveraged across Technical Dossiers, Product Presentations, Marketing Materials, and B2B Sales Pitches.
- Pre-Clinical / Clinical Readiness For products with future Clinical Trial plans, in vitro data from HFDPCs provides essential foundational evidence to support the design of next-stage testing. Anti-inflammatory data identifying target genes and effective concentrations enables rational scoping of clinical trials, reducing the risk of underpowered or misdirected studies.
Key Benefits of Cell-Level Test Data
- Mechanistic Evaluation: Assesses the potential of active ingredients or formulations to inhibit biological signals associated with inflammatory processes under controlled laboratory conditions, including studying effects on gene biomarkers critical to the hair follicle cell life cycle.
- Formulation Assessment: Confirms the biological response of finished products toward target cells.
- Technical Documentation: Quantitative RT-qPCR data is verifiable technical information that strengthens credibility in product R&D among partners and experts in the health and beauty industry.
Literature:
- Foitzik, K., Lindner, G., Mueller-Roever, S., Maurer, M., Botchkareva, N., Botchkarev, V., Handjiski, B., Metz, M., Hertel, T., & Paus, R. (2000). Control of murine hair follicle regression (catagen) by TGF-β1 in vivo. FASEB Journal, 14(5), 752–760. https://doi.org/10.1096/fasebj.14.5.752
- Inui, S., & Itami, S. (2003). Androgen-inducible TGF-β1 from balding dermal papilla cells inhibits epithelial cell growth: a clue to understand paradoxical effects of androgen on human hair growth. FASEB Journal, 17(13), 1895–1897. https://doi.org/10.1096/fj.03-0069fje
- Lawrence, T. (2009). The nuclear factor NF-κB pathway in inflammation. Cold Spring Harbor Perspectives in Biology, 1(6), a001651. https://doi.org/10.1101/cshperspect.a001651
- Kloepper, J. E., Tiede, S., Brinckmann, J., Reinhardt, D. P., Meyer, W., Faessler, R., & Paus, R. (2013). Human hair follicle dermal cells and skin fibroblasts show differential activation of NF-κB in response to pro-inflammatory challenge. Experimental Dermatology, 22(4), 278–281. https://doi.org/10.1111/exd.12098
- Zhang, Y., Andl, T., Yang, S. H., Teta, M., Liu, F., Seykora, J. T., Tobias, J. W., Piccolo, S., Schmidt-Ullrich, R., Nagy, A., Taketo, M. M., Dlugosz, A. A., & Millar, S. E. (2017). NF-κB participates in mouse hair cycle control and plays distinct roles in the various pelage hair follicle types. Journal of Investigative Dermatology, 137(12), 2490–2501. https://doi.org/10.1016/j.jid.2017.07.819
- Madaan, A., Verma, R., Singh, A. T., & Jaggi, M. (2018). Review of Hair Follicle Dermal Papilla cells as in vitro screening model for hair growth. International Journal of Cosmetic Science, 40(5), 429–450. https://doi.org/10.1111/ics.12489